文献速递头颈部肿瘤放疗

改良缩体积调强放疗在非转移性鼻咽癌中的前瞻性观察

Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma: A prospective observation series.
PubMed 文献 · Radiother Oncol · 2021-01-05

本研究在40例非转移性鼻咽癌中验证改良缩体积调强放疗(省略CTV1勾画、CTV2外扩从10mm缩至8mm)的剂量学可行性,随后应用于471例患者,中位随访46.2个月,4年LRFS、RRFS、DMFS、OS分别为96.6%、97.7%、87.7%、92.4%,局部复发均在95%等剂量线内。

要点

  • 改良缩体积IMRT省略CTV1勾画并将CTV2外扩缩至8mm,剂量学可行。
  • 471例非转移性鼻咽癌4年LRFS 96.6%、OS 92.4%,疗效未受损。
  • 全部局部复发均位于95%等剂量线内,属野内失败。

核心结论

  • 改良缩体积IMRT在非转移性鼻咽癌中可行且不损害疗效。

研究设计与样本

  • 前瞻性观察系列,先对40例非转移性鼻咽癌行剂量学分析评估改良可行性。
  • 自2014年末起将去强化技术应用于本治疗组非转移性鼻咽癌患者,共471例,中位随访46.2个月(范围3.7-70.8个月)。

主要发现

  • 剂量学评估显示该技术自然生成的60Gy等剂量曲线可良好包绕CTV1靶区。
  • 471例患者4年估计LRFS为96.6%、RRFS为97.7%、DMFS为87.7%、OS为92.4%。
  • 所有局部复发病灶均位于95%等剂量线内,被认为是野内失败。

关键数值与推荐

  • 改良缩体积IMRT省略CTV1勾画,并将CTV2外扩从10mm缩至8mm。
  • 剂量学分析中60Gy等剂量曲线可包绕CTV1靶区。

临床怎么用

  • 在非转移性鼻咽癌放疗中可考虑采用省略CTV1勾画、CTV2外扩8mm的改良缩体积IMRT。

局限性

  • 需精心设计的多中心前瞻性试验进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Although the efficacy of "reduced-volume intensity-modulated radiation therapy (IMRT)" in nasopharyngeal carcinoma (NPC) has been confirmed, two issues regarding the necessity of clinical target volume 1(CTV1) delineation and the optimal margin of CTV2 remained undetermined. The current series, utilized de-intensification technique that omitted the contouring of CTV1 and narrowed the margin of CTV2 from 10 mm to 8 mm, namely "modified reduced-volume IMRT" was initiated to evaluate the efficacy and feasibility of this renew technique in a prospective series. PATIENTS AND MATERIALS: Dosimetric analysis was performed in 40 non-metastatic NPC cases to evaluate whether our modification is feasible. Then this de-intensification technique was applied in non-metastatic NPC patients treated in our attending group since late 2014. Survival outcomes focused on local recurrence-free survival (LRFS) and local failure pattern were analyzed. RESULTS: Preliminary dosimetric evaluation of "modified reduced-volume IMRT" showed that the 60 Gy isodose curve generated naturally by this technique could well wrap the target area of CTV1. Subsequent observation series, which included a total of 471 patients and had a median follow-up time of 46.2 months(range,3.7-70.8 months), reported that 4-year estimated LRFS, regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were 96.6%, 97.7%, 87.7% and 92.4%, respectively. All local recurrence lesions occurred within 95% isodose lines and were considered in-field failures. CONCLUSIONS: Our de-intensification technique "modified reduced-volume IMRT" was feasible and did not compromise therapeutic efficacy, well-designed multicenter prospective trials are needed for further research.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Guo Q, Zheng Y, Lin J, et al. Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma: A prospective observation series. Radiother Oncol. 2021. PMID: 33418007. doi:10.1016/j.radonc.2020.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。